Novera MD review

Novera’s product pages advertise semaglutide from $94.31 a month and tirzepatide from $164.31, alongside buy-now-pay-later messaging. The pages reviewed do not explain the purchase term, upfront amount, financing terms or post-introductory cost behind those figures. They are useful starting points for a quote, not proof of month-to-month treatment at those prices.

The terms say independent licensed providers affiliated with the WizDoc network make clinical decisions; Novera is a facilitation platform. Product pages describe physician-set dosing, check-ins and follow-up labs. Ask which of those services are included in the quoted total and whether any additional laboratory bill applies. The assigned pharmacy is described generically rather than named on the reviewed product pages.

Novera’s terms say service availability varies by jurisdiction and that a live consultation may be required in some states. Both injection pages identify U.S.-compounded products. Neither a pharmacy-testing claim nor general GLP-1 research makes a compounded preparation FDA-approved. Confirm the exact product and prescribing rationale with the clinician.

Novera is more transparent about its clinical network than platforms that name no group. Its pricing still needs a complete purchase agreement, including medication quantity, recurring charges and a cancellation/refund deadline. Those details were not established from the product pages and terms reviewed, so we would not rank it as a verified $94.31 or $164.31 monthly option.